Skip to main content

Advertisement

SpringerLink
Log in

The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population

  • Review Article
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Ranolazine is an anti-anginal medication that reduces the sodium-dependent calcium overload via the inhibition of the late sodium current. After its approval for the treatment of chronic angina in 2006 in the USA, ranolazine has been reported to have several pleiotropic effects on various cardiac conditions, such as atrial fibrillation, ventricular arrhythmias, diastolic and microvascular dysfunction, and pulmonary arterial hypertension. Recently, several studies reported some promising results on the potential benefits of ranolazine on glycemic control. Though the mechanism of the antihyperglycemic effect is still unknown, ranolazine may exert the effect through β cell preservation, inhibition of glucose secretion, and enhancement of insulin secretion in a glucose-dependent manner. Given the increased risk of cardiovascular disease in patients with diabetes, it will be useful if one medication can simultaneously improve chronic angina and diabetes. Therefore, ranolazine could be a favored choice among other anti-anginal agents for patients with comorbidity of chronic angina and diabetes mellitus. In this review, we summarize the available data from clinical studies and provide valuable insight into defining the target population for the antihyperglycemic effect of ranolazine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet. 2008;372(9646):1335–41.

    Article  CAS  Google Scholar 

  2. Banerjee K, et al. Role of ranolazine in cardiovascular disease and diabetes: exploring beyond angina. Int J Cardiol. 2017;227:556–64.

    Article  Google Scholar 

  3. Gilbert BW, et al. Antihyperglycemic and metabolic effects of ranolazine in patients with diabetes mellitus. Am J Cardiol. 2018;121(4):509–12.

    Article  CAS  Google Scholar 

  4. Greiner L, Hurren K, Brenner M. Ranolazine and its effects on hemoglobin A1C. Ann Pharmacother. 2016;50(5):410–5.

    Article  CAS  Google Scholar 

  5. Zeng X, et al. Efficacy and safety of ranolazine in diabetic patients: a systematic review and meta-analysis. Ann Pharmacother. 2017:1060028017747901.

  6. Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113(20):2462–72.

    Article  Google Scholar 

  7. Dhalla AK, et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009;297(5):H1923–9.

    Article  CAS  Google Scholar 

  8. Dhalla AK, et al. Blockade of Na+ channels in pancreatic alpha-cells has antidiabetic effects. Diabetes. 2014;63(10):3545–56.

    Article  CAS  Google Scholar 

  9. Ning Y, et al. Ranolazine increases beta-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther. 2011;337(1):50–8.

    Article  CAS  Google Scholar 

  10. Fu Z, et al. Ranolazine recruits muscle microvasculature and enhances insulin action in rats. J Physiol. 2013;591(20):5235–49.

    Article  CAS  Google Scholar 

  11. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27(1):42–8.

    Article  CAS  Google Scholar 

  12. Morrow DA, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119(15):2032–9.

    Article  CAS  Google Scholar 

  13. Pettus J, et al. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obes Metab. 2016;18(5):463–74.

    Article  CAS  Google Scholar 

  14. Fanaroff AC, et al. Ranolazine after incomplete percutaneous coronary revascularization in patients with versus without diabetes mellitus: RIVER-PCI Trial. J Am Coll Cardiol. 2017;69(18):2304–13.

    Article  CAS  Google Scholar 

  15. Zack J, et al. Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus. Clin Pharmacol Drug Dev. 2015;4(2):121–9.

    Article  CAS  Google Scholar 

  16. Eckel RH, et al. Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. Diabetes Care. 2015;38(7):1189–96.

    Article  CAS  Google Scholar 

  17. Chisholm JW, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care. 2010;33(6):1163–8.

    Article  CAS  Google Scholar 

  18. Kipnes M, et al. A study to assess the metabolic effects of ranolazine when added to ongoing non-insulin medical therapy in subjects with type 2 diabetes mellitus (T2DM). Diabetes. 2011;60:A316.

    Google Scholar 

  19. Sandhiya S, et al. Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease—a randomized controlled trial. J Clin Diagn Res. 2015;9(1):OC01–5.

    PubMed  PubMed Central  Google Scholar 

  20. Lopaschuk GD, et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2003;93(3):e33–7.

    Article  CAS  Google Scholar 

  21. Greiner L, Hurren K, Brenner M. The effects of ranolazine on hemoglobin A1c in a veteran population. Fed Pract. 2018;35(5):44–8.

    PubMed  PubMed Central  Google Scholar 

  22. RANEXA® (ranolazine) extended-release tablets [package insert]. Foster City: Gilead Sciences, Inc; 2016.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, School of Pharmacy, Georgia Campus—Philadelphia College of Osteopathic Medicine, 625 Old Peachtree Rd NW, Suwanee, GA, 30024, USA

    Dusty Lisi, Chelsea Parry, Catrina Hill & Hua Ling

  2. Department of Pharmacy Practice, School of Pharmacy, Hampton University, Hampton, VA, USA

    Ebony Andrews

  3. Department of Clinical Sciences, School of Pharmacy and Department of Family and Community Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

    David Ombengi

Authors
  1. Dusty Lisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ebony Andrews
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chelsea Parry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catrina Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Ombengi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hua Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hua Ling.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lisi, D., Andrews, E., Parry, C. et al. The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population. Cardiovasc Drugs Ther 33, 755–761 (2019). https://doi.org/10.1007/s10557-019-06917-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-019-06917-6

Keywords

Search

Navigation